Medical Inactivated Influenza Vaccine->aspalthic products

Join

Help

Changchun Changsheng Life Sciences Ltd.

	Recommended Results

Medical Inactivated Influenza Vaccine

Category :

Chemicals->Chemical->aspalthic products

Product Specification

Model No:	0.5ml/syringe

Country	CN
Minimum Order	5000
Payment Term	L/C,T/T

Product Detail

[Administration and dosage] 
(1) Inject i. m. in the deltoid muscle of the lateral upper arm. 
(2) Inoculate before and during the epidemic season of influenza. Inject single human dose of 0.5 ml vaccine for adults and children aged above 3 years. Inject two human doses of 0.25 ml vaccine for children aged between 6 months and 3 years at intervals of 2-4 weeks. 
[Adverse reactions] 
Common adverse reactions 
(1) Pain, tenderness, redness, swelling and itching may occur at the injection sites generally within 24 hours after vaccination, which can be relieved spontaneously within 2-3 days in most cases.                 
(2) Transient fever may occur a and can be relieved spontaneously within a short period and need no particular treatment in most cases. 
Rare adverse reactions 
(1) Transient common cold symptoms and discomfort may occur after vaccination which can be relieved spontaneously and need no particular treatment.                 
(2) Severe fever: Physical therapy and symptomatic treatment shall be adopted to prevent febrile convulsion. 
Extremely rare adverse reactions 
(1) Allergic rash: Urticaria may occur generally within 72 hours after vaccination, if it occurs the recipients shall go to the clinic promptly and receive anti-anaphylactic treatment. 
(2) Anaphylactic shock: Anaphylactic shock may occur within one hour after vaccination, emergency measures shall be adopted immediately including prompt injection of adrenaline. 
(3) Allergic purpura: The recipients with allergic purpura shall go to t.he clinic promptly and receive anti-anaphylactic treatment with corticosteroid. If the treatment is inappropriate or delayed,  purpuric  nephritis may be complicated. 
[Contraindications] 
(l) Subjects with known allergic reaction to some components of the vaccine, including subsidiary 
materials, formaldehyde, chemicals used for virus desruption and antibiotics. 
(2) Subjects with acute diseases, severe chronic diseases, and chronic diseases at acute attack stage 
or fever. 
(3) Pregnant women. 
(4) Subjects with uncontrolled epilepsy, other progressive diseases of nervous system or a history of Guillain-Barre syndrome;



[Eligibles]


Susceptible individuals and persons liable to be afflicted with the associated complications, such as children, elderly persons and individuals in the epidemic area.


[Function and use]


The product can induce immunity against influenza virus in recipients following immunization. It is used to prevent the infections of the prevalent strains of influenza viruses.


[Description]


The influenza vaccine (split virion) is a preparation made from the WHO recommended prevalent strains of influenza virus type A and type B which are grown separately in embryonated chicken eggs. After incubation, the virus suspensions in allantoic cavities are harvested. The vaccine is prepared by inactivation, concentration, purification and disruption of the virus. It is a slightly milky-white liquid, containing thimerosal as a preservative.


Active constituent: Influenza haemagglutinin derived from each of prevalent influenza virus strains in that very year. (The name of each of virus strains and the content of haemagglutinin shall be included. )


Subsidiary materials: All the components of subsidiary materials approved shall be listed.


[Specifications]


0. 25 ml or 0.5 ml per container.  0.25 ml per single human dose (used for children aged between 6 months and 3 years) .shall contain 7.5 μg of influenza haemagglutinin of each influenza virus strain. 0.5 ml per single human dose (used for adult and children aged above 3 years) shall contain 15 μg of influenza haemagglutinin of each influenza virus strain.

<img src="http://i.bosscdn.com/product/1d/85/e4/25b2580c5f2d983e504dc14c7e.jpg@watermark=2&color=I0ZGRkZGRg%3D%3D&type=ZHJvaWRzYW5zZmFsbGJhY2s%3D&size=22&p=9&t=80&text=Y3MtdmFjY2luZS5ib3NzZ29vLmNvbQ%3D%3D" title="Infuenza Vaccine-PFS" alt="Infuenza Vaccine-PFS" /> 
ccls-vaccine.com

More Products from this Supplier

Medical Meningococcal Polysaccharide Vaccine

Prevent Hepatitis A Virus Vaccine

Attenuated Live Vaccine Chickenpox Vaccine

Group ACYW135 Meningococcal Polysaccharide Vaccine


[ Back Products Catalog ]

Commerce Member:
Please log in your ID and password, we will later fill in relating info.

ID:

Password:

Remember my ID on this computer


	Complete this form below to send out your enquiries. All enquiries will be automatically sent to the company you want to develop.

	Subject
	Content	(Don't input Company Name, E-Mail, Phone Number, Fax Number, and URL)

Company Profile:

* Company Name

*E-mail

*Country

*Contact Person

URL

*Phone

- -

Fax

- -

*Postal code

*City

*Street Address

*Business Nature

Distributor Exporter Importer Manufacturer
Whole Sale Retailer Reseller Retrofitter User
Others, please specify:

*Security Code


Enter the security code.